Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 1, 2003, Pages 25-31

  Niemi, Mikko ^a,b   Neuvonen, Mikko ^a   Juntti Patinen, Laura ^a   Backman, Janne T ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; FLUCONAZOLE; GLUCAGON; GLUCOSE; NATEGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSFORMATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; CYCLOHEXANES; DOUBLE-BLIND METHOD; FEMALE; FLUCONAZOLE; HUMANS; MALE; PHENYLALANINE; STATISTICS, NONPARAMETRIC;

EID: 0038095638     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00089-4     Document Type: Article

References (31)

1. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16.
2. Akiyoshi M, Kakei M, Nakazaki M, Tanaka H. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells. Am J Physiol 1995;268:E185-93.
3. Reunanen A, Kangas T, Martikainen J, Klaukka T. Nationwide survey of comorbidity, use, and costs of all medications in Finnish diabetic individuals. Diabetes Care 2000;23:1265-71.
4. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988;26:23-9.
5. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996;24:414-21.
6. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002;72:326-32.
7. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;69:194-200.
8. Dunn CJ, Faulds D. Nateglinide. Drugs 2000;60:607-15.
9. Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 2001;29:415-21.
10. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1993;52:29-34.
11. Anderson DM, Shelley S, Crick N, Buraglio M. A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers. Int J Clin Pharmacol Ther 2002;40:457-64.
12. Inagaki K, Takagi J, Lor E, Okamoto MP, Gill MA. Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther Drug Monit 1992;14:306-11.
13. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996;24:610-4.
14. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6.
15. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-5.
16. Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997;62:417-25.
17. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-8.
18. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998;53:445-9.
19. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000;56:225-9.
20. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996;41:319-23.
21. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996;42:465-70.
22. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-6.
23. Takesada H, Matsuda K, Ohtake R, Mihara R, Ono I, Tanaka K, et al. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent. Bioorg Med Chem 1996;4:1771-81.
24. Stockley IH. Drug interactions. 5th ed. London: Pharmaceutical Press; 1999. p. 519-20.
25. Fournier JP, Schneider S, Martinez P, Mahagne MH, Ducoeur S, Haffner M, et al. Hypoglycemic coma in a patient treated with glipizide and fluconazole: a possible interaction?, [in French]. Therapie 1992;47:446-7.
26. Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. Br J Clin Pharmacol 2001;52:456-7.
27. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994;43:403-10.
28. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997;51:415-9.
29. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
30. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51:398-407.
31. O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992;51:656-67.